Effector memory T cells, early metastasis, and survival in colorectal cancer - PubMed (original) (raw)
. 2005 Dec 22;353(25):2654-66.
doi: 10.1056/NEJMoa051424.
Anne Berger, Matthieu Camus, Fatima Sanchez-Cabo, Anne Costes, Robert Molidor, Bernhard Mlecnik, Amos Kirilovsky, Malin Nilsson, Diane Damotte, Tchao Meatchi, Patrick Bruneval, Paul-Henri Cugnenc, Zlatko Trajanoski, Wolf-Herman Fridman, Jérôme Galon
Affiliations
- PMID: 16371631
- DOI: 10.1056/NEJMoa051424
Free article
Effector memory T cells, early metastasis, and survival in colorectal cancer
Franck Pagès et al. N Engl J Med. 2005.
Free article
Abstract
Background: The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown.
Methods: We studied pathological signs of early metastatic invasion (venous emboli and lymphatic and perineural invasion) in 959 specimens of resected colorectal cancer. The local immune response within the tumor was studied by flow cytometry (39 tumors), low-density-array real-time polymerase-chain-reaction assay (75 tumors), and tissue microarrays (415 tumors).
Results: Univariate analysis showed significant differences in disease-free and overall survival according to the presence or absence of histologic signs of early metastatic invasion (P<0.001). Multivariate Cox analysis showed that an early conventional pathological tumor-node-metastasis stage (P<0.001) and the absence of early metastatic invasion (P=0.04) were independently associated with increased survival. As compared with tumors with signs of early metastatic invasion, tumors without such signs had increased infiltrates of immune cells and increased levels of messenger RNA (mRNA) for products of type 1 helper effector T cells (CD8, T-BET [T-box transcription factor 21], interferon regulatory factor 1, interferon-gamma, granulysin, and granzyme B) but not increased levels of inflammatory mediators or immunosuppressive molecules. The two types of tumors had significant differences in the levels of expression of 65 combinations of T-cell markers, and hierarchical clustering showed that markers of T-cell migration, activation, and differentiation were increased in tumors without signs of early metastatic invasion. The latter type of tumors also had increased numbers of CD8+ T cells, ranging from early memory (CD45RO+CCR7-CD28+CD27+) to effector memory (CD45RO+CCR7-CD28-CD27-) T cells. The presence of high levels of infiltrating memory CD45RO+ cells, evaluated immunohistochemically, correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival.
Conclusions: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Copyright 2005 Massachusetts Medical Society.
Comment in
- Tumor-infiltrating T cells--friend or foe of neoplastic cells?
Parmiani G. Parmiani G. N Engl J Med. 2005 Dec 22;353(25):2640-1. doi: 10.1056/NEJMp058236. N Engl J Med. 2005. PMID: 16371629 No abstract available. - Immune cells in colorectal cancer.
Wolf D, Marth C, Wolf AM. Wolf D, et al. N Engl J Med. 2006 Apr 6;354(14):1531-2; author reply 1531-2. doi: 10.1056/NEJMc060116. N Engl J Med. 2006. PMID: 16598053 No abstract available.
Similar articles
- CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival.
Koelzer VH, Lugli A, Dawson H, Hädrich M, Berger MD, Borner M, Mallaev M, Galván JA, Amsler J, Schnüriger B, Zlobec I, Inderbitzin D. Koelzer VH, et al. J Transl Med. 2014 Mar 29;12:81. doi: 10.1186/1479-5876-12-81. J Transl Med. 2014. PMID: 24679169 Free PMC article. - OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B, Cremonesi E, Sorge R, Muraro MG, Delko T, Nebiker CA, Däster S, Governa V, Amicarella F, Soysal SD, Kettelhack C, von Holzen UW, Eppenberger-Castori S, Spagnoli GC, Oertli D, Iezzi G, Terracciano L, Tornillo L, Sconocchia G, Droeser RA. Weixler B, et al. Oncotarget. 2015 Nov 10;6(35):37588-99. doi: 10.18632/oncotarget.5940. Oncotarget. 2015. PMID: 26439988 Free PMC article. - In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. Pagès F, et al. J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858404 - Low expression of Granzyme B in colorectal cancer is associated with signs of early metastastic invasion.
Salama P, Phillips M, Platell C, Iacopetta B. Salama P, et al. Histopathology. 2011 Aug;59(2):207-15. doi: 10.1111/j.1365-2559.2011.03915.x. Histopathology. 2011. PMID: 21884199 - Neutrophil-to-Lymphocyte Ratio and Intratumoral CD45RO-Positive T Cells as Predictive Factors for Longer Survival of Patients with Colorectal Liver Metastasis after Hepatectomy.
Hamada T, Ishizaki H, Haruyama Y, Hamada R, Yano K, Kondo K, Kataoka H, Nanashima A. Hamada T, et al. Tohoku J Exp Med. 2020 Aug;251(4):303-311. doi: 10.1620/tjem.251.303. Tohoku J Exp Med. 2020. PMID: 32779620
Cited by
- Construction and validation of an immune-related gene signature predictive of survival and response to immunotherapy for colorectal cancer.
Li C, Chen M, Liu M, Yuan Z. Li C, et al. Medicine (Baltimore). 2024 Oct 4;103(40):e39798. doi: 10.1097/MD.0000000000039798. Medicine (Baltimore). 2024. PMID: 39465758 Free PMC article. - Machine learning-based model for CD4+ conventional T cell genes to predict survival and immune responses in colorectal cancer.
Wang Z, Sun Z, Lv H, Wu W, Li H, Jiang T. Wang Z, et al. Sci Rep. 2024 Oct 18;14(1):24426. doi: 10.1038/s41598-024-75270-y. Sci Rep. 2024. PMID: 39424871 Free PMC article. - Risk of recurrence in early-onset versus late-onset non-metastatic colorectal cancer, 2004-2019: a nationwide cohort study.
Nors J, Gotschalck KA, Erichsen R, Andersen CL. Nors J, et al. Lancet Reg Health Eur. 2024 Oct 3;47:101093. doi: 10.1016/j.lanepe.2024.101093. eCollection 2024 Dec. Lancet Reg Health Eur. 2024. PMID: 39421193 Free PMC article. - P2 purinergic receptor expression and function in tumor-related immune cells.
Manoharan V, Adegbayi OO, Maynard JP. Manoharan V, et al. Purinergic Signal. 2024 Oct 10. doi: 10.1007/s11302-024-10054-7. Online ahead of print. Purinergic Signal. 2024. PMID: 39387963 Review. - Integrative analysis of H&E and IHC identifies prognostic immune subtypes in HPV related oropharyngeal cancer.
Nakkireddy SR, Jang I, Kim M, Yin LX, Rivera M, Garcia JJ, Bartemes KR, Routman DM, Moore EJ, Abdel-Halim CN, Ma DJ, Van Abel KM, Hwang TH. Nakkireddy SR, et al. Commun Med (Lond). 2024 Oct 3;4(1):190. doi: 10.1038/s43856-024-00604-w. Commun Med (Lond). 2024. PMID: 39363031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials